English
Women Care in Broadway

Women Care

Women Care Program in Broadway

Women's care in haematology is a specialised field focusing on the diagnosis, treatment, and management of blood disorders unique to women or those presenting atypically compared to men. One of the primary concerns is menorrhagia (excessive menstrual bleeding), which can indicate underlying haematological conditions such as von Willebrand disease or platelet function disorders. These conditions often require integrated management strategies addressing both gynaecological and haematological aspects.

Another crucial area is the management of haematological disorders during pregnancy. Conditions such as thrombocytopenia, thrombophilias, and iron deficiency anaemia can arise, impacting maternal and fetal health. Effective prenatal and postpartum care necessitates regular monitoring and management of these disorders to ensure optimal outcomes for both mother and child.

Moreover, haematological abnormalities, including anaemia or coagulopathies, may also be associated with gynaecological malignancies such as cervical, uterine, and ovarian cancers. A multidisciplinary approach involving haematologists, gynaecologists, and oncologists is essential for the comprehensive management of these cancers, ensuring holistic care for the patient.

Consult our haematologists if you need services related to Women's Care in Haematology in Broadway.

Our women's care program provides a yearly exam with a Pap test and screenings for breast disease, hormonal imbalances, and osteoporosis. Book an appointment for the best women's's care hospital at Manipal

FAQ's

Iron deficiency anaemia brought on by menstruation and pregnancy-related blood loss, thrombocytopenia such as immune thrombocytopenic purpura (ITP), and von Willebrand disease, which causes increased menstrual bleeding, are common haematological illnesses that disproportionately impact women. Women are more likely than men to suffer from autoimmune hemolytic anaemia, lupus, antiphospholipid syndrome, menorrhagia, and thrombophilia. Due to the distinct physiological requirements of women, these illnesses frequently call for specialised therapy.
 

Menstruation causes blood loss, which can lower haemoglobin and hematocrit levels and, if iron stores are not restored, eventually result in iron deficiency anaemia. Anaemia can be exacerbated by conditions such as von Willebrand disease or platelet function problems, which can cause irregular menstrual flow. Hormonal imbalances, like those found in polycystic ovarian syndrome, can also cause haematological problems and irregular menstruation. For women's health, treating these abnormalities and taking care of underlying illnesses are essential.
 

During pregnancy, it is crucial to consider certain haematological factors in order to safeguard the well-being of both the mother and the foetus. Pregnancy brings about physiological changes, such as increased blood volume and heightened susceptibility to various diseases, including thrombocytopenia, iron deficiency anaemia, thromboembolic disorders, and Rh incompatibility. To ensure optimal health for both the mother and the foetus, management methods encompass iron supplementation, regular haematological testing, prenatal screening, preventive treatments like anticoagulant therapy, and, if necessary, blood transfusions.
 

The alterations in hormones that occur during adolescence, pregnancy, and menopause have a substantial effect on a woman's blood health. The increase of oestrogen during puberty affects bone marrow function and blood cell formation. In contrast, the oestrogen-depleting menopause may increase the risk of anaemia. Hemodilution and increased iron requirements are caused by pregnancy. Personalised treatment plans are essential for maintaining a woman's haematological health across her lifetime.
 

Hormonal contraceptives, such as pills, patches, and rings, increase the risk of thrombosis because progestins cause venous stasis and oestrogen promotes clots. Healthcare professionals perform in-depth examinations and take into account alternatives for high-risk individuals in order to reduce this danger. They might advise patients to modify their lifestyles or monitor them for thrombotic symptoms while prescribing low-dose oestrogen. The advantages of hormonal contraceptives should be weighed against the danger of thrombosis and handled appropriately, even with their efficacy.
 

Haematological symptoms include anaemia from prolonged blood loss and thrombocytosis as a result of the inflammatory response, which can result from gynaecological malignancies. There may also be coagulopathies, such as disseminated intravascular coagulation. Tumour markers and haematological parameters support therapy monitoring and diagnosis. Specialists working together to provide comprehensive care guarantee supportive measures for haematological problems. Gaining knowledge about these expressions improves therapy results and early detection.
 

There are several challenges in diagnosing and treating iron deficiency anaemia (IDA) in women, particularly during pregnancy and menstruation. The diagnosis is made more difficult by the overlap of symptoms with typical physiological changes. Increased iron requirements during pregnancy could be impeded by problems with absorption or adverse effects from supplements. Close observation and treatment of IDA are necessary; however, managing the condition is made more difficult by administrative obstacles and underlying causes such as gastrointestinal haemorrhage. To optimise results, addressing these difficulties requires a comprehensive strategy.
 

Women's haematological health depends on the von Willebrand factor (vWF), which promotes platelet adhesion and clotting. The hallmark of von Willebrand disease (vWD) is inadequate or faulty vWF, which causes excessive bleeding during the menstrual cycle, delivery, or surgical procedures. Correct diagnosis via lab testing, desmopressin for mild to moderate cases, replacement therapy for severe vWD, hormonal contraceptives to control bleeding, antifibrinolytic drugs, and multidisciplinary care are all part of management, which guarantees individualised treatment regimens for the best possible haematological health.